Skip to content

Multi-cycle Prolon Diet

Effect of a Periodic Fasting-mimicking Diet on Risk Factors for Metabolic Syndrome and Age-related Diseases

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02158897
Enrollment
102
Registered
2014-06-09
Start date
2013-03-31
Completion date
2016-06-30
Last updated
2017-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

Evidence from bio-gerontology research from our laboratory and others have showed that short-term fasting/starvation (STS) can improve the efficacy of chemotherapy by protecting normal cells and tissues and potentially sensitizing malignant cells to chemo drugs. Furthermore, STS improves risk factors associated with aging and age-related disease in rodent models. Prolonged fasting, however, is difficult to implement and may not be feasible or safe in humans. We have developed a fasting-mimicking diet (FMD) that was well accepted in a pilot human trial. The objective of the study is to ascertain the impact of the fasting-mimicking diet given to adult subjects for 5 days a month for 3 consecutive months. The investigators hypothesize that the specially designed dietary regimen can reduce the risk factors for metabolic syndrome and biomarkers associated with aging and age-related diseases.

Detailed description

The Phase I part of the study is designed as a randomized cross-over trial, including two arms: a Control arm and a multi-cycle special 5-day dietary regimen (Diet, 3 cycles) arm. After 3 cycles, the Control and Diet groups are crossed over such that the Control group will under-go dieting and the Diet group will return to normal diet. Participants will be monitored for body weight and physiological changes, as well as the adherence to the dietary intervention. The Phase II part of the study is an expansion of the Phase I to ascertain the impact of the dietary intervention on risk factors for metabolic syndrome and biomarkers associated with aging and age-related diseases. Statistical methods: Paired samples t-test and Mann-Whitney test will be used to compare between Control and Diet groups as well as pre- and post-diet values.

Interventions

3 cycles of a 5-day Prolon diet very month

Sponsors

University of Southern California
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Generally healthy adults * BMI \>19 kg/m\^2

Exclusion criteria

* Severe hypertension (systolic BP \> 200 mm Hg and/or diastolic BP \> 105 mm Hg). * Underweight (BMI \< 19 kg/m\^2) * Females who are pregnant or nursing * Special dietary requirements incompatible with the study interventions * Significant food allergies which would make the subject unable to consume the study food * Alcohol dependency (alcohol intake greater than two drinks per day for women and three drinks per day for men).

Design outcomes

Primary

MeasureTime frameDescription
Safety and feasibility of the Prolon diet1 and half yearsPhase I: To obtain preliminary estimates of the feasibility and safety of a low calorie Prolon diet in adult subjects.
Effect of Prolon diet on risk factors for metabolic syndrome and biomarkers of aging2 and half yearsPhase II: To ascertain the impact of the calorie restricted special diet on the risk factors for metabolic syndrome and biomarkers associated with aging and age-related diseases: e.g. fasting glucose, glucose tolerance, blood pressure, abdominal obesity, lipid profile, circulating IGF-1 and IGFBP1.

Secondary

MeasureTime frameDescription
Changes in cognitive functions before and after the dietary intervention.2 and half yearsEffects of dieting on the brain using fMRI; Effects of dieting on cognitive functions: 1. Verbal memory and learning; 2. Speed of processing/attention; 3. Working memory; 4. Executive function; 5. Visuospatial construction and memory; 6. Frequency of Forgetting;

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026